Agostino Tafuri

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 09, 2026

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: JCO oncology practice

Published: May 27, 2026

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Journal: Cancers

Published: January 08, 2026

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene.

A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene.

Journal: Current research in translational medicine

Published: September 18, 2025

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Journal: British journal of haematology

Published: September 07, 2025

Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).

Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).

Journal: British journal of haematology

Published: March 25, 2025

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Journal: Annals of hematology

Published: March 25, 2025

Luspatercept in lower-myelodysplastic syndromes (MDS): Real-world data from the Gruppo Romano-Laziale Mielodisplasie (GROM-L) and review of literature.

Luspatercept in lower-myelodysplastic syndromes (MDS): Real-world data from the Gruppo Romano-Laziale Mielodisplasie (GROM-L) and review of literature.

Journal: Leukemia research

Published: March 09, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Journal: Leukemia

Published: March 04, 2025

MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study.

MRD Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study.

Journal: American journal of hematology

Published: February 27, 2025

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.

Journal: Leukemia

Published: February 13, 2025

Showing 1-12 of 105

Last Updated: 09/26/2026